{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:52:33Z","timestamp":1786600353795,"version":"build-2736575974"},"reference-count":29,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,6,12]],"date-time":"2022-06-12T00:00:00Z","timestamp":1654992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate the correlation of inflammatory cytokines with the treatment response to tumor necrosis factor inhibitor (TNFi) in axial spondyloarthritis (axSpA) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study enrolled 86 axSpA patients and 20 healthy controls (HCs). Inflammatory cytokines including tumor necrosis factor\u2010\u03b1 (TNF\u2010\u03b1), interleukin (IL)\u20101\u03b2, IL\u20106, IL\u201012, IL\u201017A, IL\u201021, IL\u201023, and IL\u201032 were determined in serum samples of axSpA patients before treatment and in HCs after enrollment. All patients received 40\u2009mg adalimumab every 2\u2009weeks for 12\u2009weeks; meanwhile, ASAS40 (40 criteria of the Assessment by the SpondyloArthritis International Society) response rates were evaluated at weeks 2, 4, 8, and 12.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Most inflammatory cytokines were elevated in axSpA patients compared with HCs (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) except for IL\u201032 (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.101). In axSpA patients, ASAS40 response rates were 0%, 19.5%, 34.5%, 47.1%, and 56.3% at weeks 0, 2, 4, 8, and 12, respectively. Baseline [interquartile range] IL\u20106 (47.3 [32.5\u201053.4] pg\/mL vs 31.7 [23.0\u201050.9] pg\/mL, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.005) and IL\u201017A (127.9 [90.7\u2010149.5] pg\/mL vs 96.6 [56.1\u2010112.6] pg\/mL, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) were higher in axSpA patients with ASAS40 response compared with those without ASAS40 response, while baseline TNF\u2010\u03b1, IL\u20101\u03b2, IL\u201012, IL\u201021, IL\u201023, and IL\u201032 were not different between them (all <jats:italic>P<\/jats:italic>\u2009&gt;\u20090.050). Multivariate logistic regression analysis disclosed that baseline IL\u201017A (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.037), C\u2010reactive protein (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.012), and history of TNF inhibitor (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.029) were independently associated with ASAS40 response. Furthermore, baseline IL\u201017A, C\u2010reactive protein, history of TNFi, and their combination had an acceptable to good ability for predicting ASAS40 response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Measurement of pre\u2010treatment inflammatory cytokine levels is valuable for predicting treatment efficacy of TNFi in axSpA patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.14353","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T06:59:53Z","timestamp":1655103593000},"page":"844-850","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Measurement of pre\u2010treatment inflammatory cytokine levels is valuable for prediction of treatment efficacy to tumor necrosis factor inhibitor in axial spondyloarthritis patients"],"prefix":"10.1111","volume":"25","author":[{"given":"Fei","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Traditional Chinese Medicine, Section of Western Medicine Foundation Teaching and Research Baoji Vocational &amp; Technical College  Baoji China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology Baoji Central Hospital  Baoji China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Wen","sequence":"additional","affiliation":[{"name":"Department Neurology Baoji Central Hospital  Baoji China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology No.215 Hospital of Shaanxi Nuclear Industry  Xianyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-4640","authenticated-orcid":false,"given":"Yuping","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology Baoji Central Hospital  Baoji China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406182"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14175"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14030"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.602334"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2017.1330419"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05628-4"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab245"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-0148-4"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14304"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2020-0305"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08823-4"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14236"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14028"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-018-0530-9"},{"issue":"136","key":"e_1_2_8_16_1","first-page":"2277","article-title":"Effects of mucosal TNF\u2010alpha levels on treatment response in Crohn's disease patients receiving anti\u2010TNF treatment","volume":"61","author":"Vatansever A","year":"2014","journal-title":"Hepato\u2010Gastroenterology"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4072"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202533"},{"issue":"5","key":"e_1_2_8_20_1","first-page":"611","article-title":"Baseline Interleukin\u20106 and erythrocyte sedimentation rate can predict clinical response of TNF inhibitor treatment in patients with ankylosing spondylitis","volume":"49","author":"Dong Y","year":"2019","journal-title":"Ann Clin Lab Sci"},{"issue":"10","key":"e_1_2_8_21_1","first-page":"17362","article-title":"Elevated serum levels of IL\u20106 and IL\u201017 may associate with the development of ankylosing spondylitis","volume":"8","author":"Liu W","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roab039"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00231"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-021-00854-3"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3369"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.09.023"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-019-00624-2"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2019.1660402"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12738"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.109702"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.14353","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1756-185X.14353","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.14353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T21:12:40Z","timestamp":1692738760000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.14353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,12]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/1756-185X.14353"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.14353","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,12]]},"assertion":[{"value":"2021-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}